Alkermes Patent-Cliff Exposure & CMS Drug Spending Portfolio

Alkermes (Waltham, MA): 5 reconciled FDA prescription therapies (76.5% 2025 to 2030 cliff risk), $1.32B 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterWaltham, MA
Reconciled FDA Portfolio Therapies5
2025 to 2030 Patent-Cliff Revenue Exposure76.5%
Primary Portfolio LOE Date2029-01-01
2024 CMS Total Public Spend$1.32B
2024 Medicare Part D Spend$488.6M
2024 Medicaid Spend$833.5M
California HCAI SB 17 Filings8 WAC filings (max 19.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Alkermes across sibling Meru public-data platforms.